1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. US Prostate Cancer Nuclear Medicine Diagnostics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. US Prostate Cancer Nuclear Medicine Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. US Prostate Cancer Nuclear Medicine Diagnostics Market Regional Analysis
6.2 US Prostate Cancer Nuclear Medicine Diagnostics Market Revenue 2017-2027 (US$ Million)
6.3 US Prostate Cancer Nuclear Medicine Diagnostics Market Forecast Analysis
7. US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – by Type
7.1 SPECT
- 7.1.1 Overview
- 7.1.2 SPECT: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 PET
- 7.2.1 Overview
- 7.2.2 PET: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – by PET Product
8.1 F-18
- 8.1.1 Overview
- 8.1.2 F-18: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 C11
- 8.2.1 Overview
- 8.2.2 C11: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 GA 68 PSMA
- 8.3.1 Overview
- 8.3.2 GA 68 PSMA : US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. US Prostate Cancer Nuclear Medicine Diagnostics Market – United States Analysis
9.1 Overview
9.2 United States
- 9.2.1 US Prostate Cancer Nuclear Medicine Diagnostics Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 9.2.1.1 US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and
Forecast Analysis – by Country
- 9.2.1.1 United States :
US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2027 (US$ Million)
- 9.2.1.1.1 United States : US Prostate Cancer Nuclear Medicine Diagnostics Market Breakdown, by Type
- 9.2.1.1.2 United States : US Prostate Cancer Nuclear Medicine Diagnostics Market Breakdown, by PET Product
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments
12. Company Profiles
12.1 Blue Earth Diagnostics Limited
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Progenics Pharmaceuticals, Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 CURIUM
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Telix Pharmaceuticals Ltd.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 NCM-USA LLC
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 ABX Advanced Biochemical Compounds GmbH
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Jubilant Radiopharma
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Lantheus Medical Imaging, Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Advanced Accelerator Applications (Novartis AG)
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Theragnostics
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
Get Free Sample For US Prostate Cancer Nuclear Medicine Diagnostics Market
